Story perspectives

Abbott Labs Misses Revenue, Yet Shares Rise Slightly

7/17/2025

43 9

Summary

Story summary

Abbott Laboratories (ABT) reported Q3 2024 revenue of $10.6 billion, falling short of estimates by $60 million, yet shares increased by 0.71% pre-market.
The Medical Devices segment experienced robust growth, particularly in Diabetes Care and Heart Failure products.
Analysts express optimism despite reduced 2025 sales guidance, noting strong Medtech performance and strategic partnerships.
Abbott's stock declined 6.30% due to broader challenges in the healthcare sector, reflecting market volatility.

History

Historical Context

The Affordable Care Act, enacted in 2010, significantly increased healthcare access, resulting in a 30% rise in insured Americans and heightened demand for medical devices. Abbott Laboratories, which has expanded its portfolio through acquisitions, reported $10.6 billion in Q3 2024 revenue, reflecting ongoing challenges in the healthcare sector amid market volatility and evolving Medtech strategies.

1 of 2

Story summary

Abbott Laboratories (ABT) reported Q3 2024 revenue of $10.6 billion, falling short of estimates by $60 million, yet shares increased by 0.71% pre-market.
The Medical Devices segment experienced robust growth, particularly in Diabetes Care and Heart Failure products.
Analysts express optimism despite reduced 2025 sales guidance, noting strong Medtech performance and strategic partnerships.
Abbott's stock declined 6.30% due to broader challenges in the healthcare sector, reflecting market volatility.

1 / 2